Sana Biotechnology

Pancreatic cells
#allogeneic cell therapies #Cell therapy #Diabetes #Sana Biotechnology #Type 1 diabetes

First evidence of cell transplant without immunosuppression

Positive results have been revealed from the first-in-human study transplanting an islet cell therapy into a patient with type 1 diabetes without the use of immunosuppression.  The study was investigating Sana Biotechnology’s UP421, an allogeneic primary islet cell therapy that has been engineered with… Read More

#News #Trending News

Diabetes patient injecting insulin
#allogeneic cell therapies #Cell therapy #Sana Biotechnology #Stem cell transplant #Type 1 diabetes

Insulin independence without immunosuppression

Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). The study results were published in Cell Stem Cell, in a paper titled ‘Hypoimmune islets achieve insulin independence after allogeneic transplantation in a… Read More

#Editor's Choice #News